Clinical TrialJul 14, 2026, 07:03 AM
Kura Oncology to Present Updated Darlifarnib Phase 1a Data at KCRS
AI Summary
Kura Oncology announced updated Phase 1a results from its FIT-001 clinical trial, evaluating darlifarnib in combination with cabozantinib for advanced renal cell carcinoma (RCC), will be presented at the 2026 Kidney Cancer Research Summit. The data is expected to further support darlifarnib's potential to enhance VEGFR-targeted therapies. The company is also enrolling patients in a randomized Phase 1b study and plans a registrational Phase 3 study for 2028. Kura Oncology will host an investor call on July 27, 2026, to discuss these updates.
Key Highlights
- Updated Phase 1a results for darlifarnib + cabozantinib in advanced ccRCC to be presented at KCRS.
- Data from FIT-001 Phase 1a study will highlight long-term follow-up in heavily pretreated patients.
- Results expected to support darlifarnib's potential to enhance VEGFR-targeted therapy in ccRCC.
- Global randomized Phase 1b study comparing darlifarnib + cabozantinib vs. cabozantinib alone is ongoing.
- Phase 1b study aims to inform recommended Phase 3 dose for a registrational study planned for 2028.
- Kura Oncology will host a virtual investor call on July 27, 2026, at 8:00 a.m. ET.
Price Impact
More from KURA